Royal Caribbean's earnings yesterday showed a company defiant to the economic burdens that has the rest of the business world hedging bets, yanking guidance, and dialing back expectations.
(Jeff Whyte/Shutterstock)
 
Presented by
Hey Snackers,
Amazon had… an unusual day. First, news emerged that Amazon would list tariff costs next to prices on its site (as Temuis already doing), leading the White House to call the move a "hostile and political act" in a morning press conference. Then Amazon said, no no no, we were only thinking about doing that on Amazon Haul! But the story first started because of a post on Punchbowl that appears to be sponsored by, you guessed it, Amazon. Looking forward to listening to its earnings call tomorrow!
Royal Caribbean's earnings yesterday showed a company defiant to the economic burdens that has the rest of the business world hedging bets, yanking guidance, and dialing back expectations.
We've seen company after company stare down a volatile trade situation and an American consumer whose financial security has been checked over the past several weeks, and what have we seen? Adjusted guidance, and not in a good direction.
Royal Caribbean scoffs at this! Based on what it's seeing, the American consumer will spend their bottom dollar if that's what it takes to get on a cruise ship this year. Bookings are on track, cancellation levels are normal, and close-in demand is great, the company says.
Lower guidance? To Davy Jones' Locker, go ye!
No, Royal Caribbean saw the world for what it is and made the assessment that demand for frozen drinks in pools floating in the Caribbean will be existentially necessary to huge swaths of the American populace.
THE TAKEAWAY
Damn the torpedoes and full speed ahead — Royal Caribbean raised guidance, now anticipating full-year earnings per share between $14.55 and $15.55, up from its prior forecast of $14.35 to $14.65.
Not Funded by Big Pharma. Not Distracted by Wall Street.
Most biotech startups chase venture dollars or Big Pharma buyouts. Not Cytonics.
Big Pharma has failed to deliver a disease-modifying therapy for osteoarthritis (DMOAD) — but Cytonics refuses to accept that. By genetically enhancing a naturally occurring blood protein called A2M, they've created CYT-108 — a groundbreaking biologicpoised to become the first true disease-modifyingtherapy for osteoarthritis.
Cytonics has raised exactly $0.00 from venture capital giants and is funding the development of CYT-108 from everyday investors — and now, they're preparing to enter a pivotal Phase 2 trial
Tariff exemption is coming for automakers, or at least for their vehicles made from 85% US content.
For a year, cars that are made with at least 85% domestic and USMCA-compliant content will be able to apply for full reimbursement from tariffs, according to a Wall Street Journal report that cited a senior US official. After a year, that percentage goes up to 90%.
None of the big three automakers are anywhere close. As of last year, the average US content for Ford vehicles was 54%, tied with GM. Each of them is well above the 46% American content at Stellantis, which makes Jeep and Dodge.
Honda is the closest to the mark for major automakers, with 63% average US content for its vehicles, well above fellow Japanese automakers with major American presences Toyota (29%) and Nissan (24%).
At Tesla, the company owned largely by Elon Musk, a close confidant to the man instrumental in developing and executing administration policy, that figure is 81%.
THE TAKEAWAY
Tariffs have thrown a spanner in the works for automakers, which are major manufacturing employers. Just yesterday, GM had to postpone its investor call following claims of possible tariff relief. Realistically, it's incredibly hard to operate with this much uncertainty, and it's this exact kind of company that serves as the flagship of the US industrial base.
The $123 million that "Sinners" — a completely original movie in a slate typically awash with sequels and recycled IP — has grossed at the domestic box office so far is scaring up a near record for horror.
Cytonics is a leading example of grassroots biotech: real science, real patients, and real traction. Get in alongside real, everyday investors — not Wall Street or Silicon Valley.1
Investing in private company securities is not suitable for all investors because it is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities.
 
Was this email forwarded to you? Don't miss out on future stories — subscribe to Snacks and get your daily dose of financial news straight to your inbox.
Craving more insights in your inbox? Subscribe to Chartr and The Wrap for quality reads.
 
Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate... See more
